Precision medicine relies on understanding tumor behavior at the DNA level. Yet, one of the most critical mechanisms – DNA repair defects – remains under-detected in clinical practice, despite affecting millions of patients worldwide. These abnormalities, whether hereditary or acquired, promote cancer development and strongly influence treatment response. MSInsight addresses this blind spot by making it detectable and actionable routinely, directly from existing genomic data – without additional tests, without delays, and with unprecedented precision in clinical settings.
The next step
MSInsight is entering a pivotal phase: obtaining CE-IVDcertification, which will pave the way for the software's deployment in clinical practice across Europe. Concurrently, the team is looking to add a business development expert to structure its commercial growth and accelerate its market entry.
Why 21st by CentraleSupélec?
Moving from proof of concept to market is often the most complex challenge for a health deeptech. This is precisely where 21st by CentraleSupélec comes in: by supporting MSInsight with its strategy for fundraising, the incubator provides it with the resources and connections needed to achieve this milestone with ambition.
Focus on the founder
contact@msinsight.tech | www.msinsight.tech
#Genomics #Diagnostics #Oncology #Bioinformatics #PrecisionMedicine
.avif)
